A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey).

Center for Research of Diabetes, Metabolism and Nutrition and 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University Prague, Czech Republic.
Diabetic Medicine (Impact Factor: 3.24). 11/2008; 25(10):1195-203. DOI: 10.1111/j.1464-5491.2008.02570.x
Source: PubMed

ABSTRACT The objective of this study was to assess diabetes care in outpatient diabetes clinics in the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.
Questionnaires for each randomly enrolled patient were completed by an endocrinologist or diabetologist. Data concerning age, sex, diabetes duration, diabetes type, treatment type, glycated haemoglobin (HbA(1c)), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C), blood pressure (BP) and short- and long-term diabetes complications were recorded. Questionnaires were analysed centrally for each country and stratified for Type 1 diabetes (T1D), Type 2 diabetes (T2D) and other types of diabetes.
Data on 10 950 individuals were analysed (mean population age 56.2 years; females 52%; T1D 22.9%; T2D 75.3%; mean time from diagnosis 11 years). Patients with HbA(1c) within target (< 6.5%): T1D 13.1%, T2D 21.4%; for TC levels (< 4.5 mmol/l): T1D 37%, T2D 20%; for TG levels (< 1.7 mmol/l): T1D 78%, T2D 44%; for HDL-C (> 1.1 mmol/l): T1D 81%, T2D 60%; for LDL-C (< 2.5 mmol/l): T1D 36%, T2D 23%; for BP (< 130/80 mm Hg): T1D 42%, T2D 9%. The prevalence of severe hypoglycaemia (within the last 6 months) was 12% in T1D and 2% in T2D. Prevalence of diabetic ketoacidosis was 0.3-6.6%, blindness 0.15-1.3% and diabetic nephropathy 19-42%.
The data show the current quality of care and potential areas for improvement. The quality of care is generally comparable with that in Western Europe.

  • [Show abstract] [Hide abstract]
    ABSTRACT: GPs' and patients' socio-demographic characteristics were investigated as possible, determinants of ophthalmologic examination referral rates among type 2 diabetes mellitus patients. Female GPs were more effective among retinopathy-free patients, while male GPs among patients with retinopathy. It could be explained by the gender related authority-empathy balance, manifested, through communication style.
    Diabetes research and clinical practice 10/2013; · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION In 2011, Diabetes Poland updated its recommended goals in diabetes treatment, including HbA1c and blood pressure (BP) levels. Adherence to the updated guidelines has not been systematically assessed. OBJECTIVES The aim of the study was to assess which methods are most commonly used in the treatment of recently diagnosed type 2 diabetes and to what extent the new criteria for diabetes control are met in these patients. PATIENTS AND METHODS ARETAEUS2-Grupa was a cross-sectional questionnaire-based study conducted in Poland in 2012 (April-June). It involved 1636 patients of any age and sex, with type 2 diabetes diagnosed within the previous 2 years, recruited by randomly selected physicians. RESULTS Of all patients, 37.5% met the goal of the glycated hemoglobin (HbA1c) level of ≤6.5% (recommended in type 2 diabetes of short duration), while 62% met the goal of HbA1c level of ≤7% (general recommendation). Only 6.7% of the patients met all 3 goals (HbA1c ≤6.5%, BP <140/90, and LDL-cholesterol <100 mg/dl or <70 mg/dl with coronary heart disease), 29.7% met 2 goals, 36.8% met only 1 goal, while 26.7% did not meet any of the treatment goals. With the use of the HbA1c level recommended for the overall population, the proportions of patients meeting 3, 2, and 1 goals increased to 11%, 34.5%, and 35.5%, respectively, while the percentage of the patients not meeting any of the goals decreased to 18%. Metformin in monotherapy or in combination was the most commonly used drug in the study population (80%). CONCLUSIONS The great majority of the patients with type 2 diabetes of short duration did not meet all of the treatment goals as recommended in the current practice guidelines. When the treatment goals were used for the overall population (HbA1c ≤7%), a slightly higher, but still unsatisfactory, proportion of the patients met all the treatment goals. Metformin alone or in combination was the most commonly used drug in the study population.
    Polskie archiwum medycyny wewnȩtrznej 09/2013; · 2.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence suggesting that structured SMBG is beneficial for all type 2 diabetes patients, regardless of therapy. However, access to SMBG can be limited in many countries in Central and Eastern Europe. A consensus group of diabetes experts from 10 countries in this region (with overlapping historical, political, and social environments)-Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine-was formed to discuss the role of SMBG across the spectrum of patients with diabetes. The group considered SMBG to be an essential tool that should be accessible to all patients with diabetes, including those with non-insulin-treated type 2 diabetes. The current article summarizes the evidence put forward by the consensus group and provides their recommendations for the appropriate use of SMBG as part of individualized patient management. The ultimate goal of these evidence-based recommendations is to help patients and providers in Central and Eastern Europe to make optimal use of SMBG in order to maximize the efficacy and safety of glucose-lowering therapies, to prevent complications, and to empower the patient to play a more active role in the management of their diabetes.
    Diabetes Technology &amp Therapeutics 04/2014; · 2.29 Impact Factor


Available from
May 26, 2014